Demographic and clinical data for 111 patients with Parkinson's disease
| 1993 | 1997 | p Value1-150 | Mean change (SD) | 95% CI1-151 | |
| Age (y) (mean (SD)) | 69.8 (8.0) | ||||
| No of women (%) | 63 (56.8) | ||||
| Duration of disease (y) (mean (SD)) | 8.5 (5.0) | ||||
| Duration of medication (y) (mean (SD)) | 6.0 (4.5) | ||||
| UPDRS score (mean (SD)) | |||||
| Mental | 2.6 (1.9) | 3.8 (2.8) | 0.000 | 1.2 (2.7) | (0.7 to 1.7) |
| ADL | 10.3 (6.7) | 16.8 (9.6) | 0.000 | 6.5 (7.1) | (5.1 to 7.8) |
| Motor | 21.2 (12.4) | 29.2 (19.1) | 0.000 | 7.9 (13.6) | (5.3 to 10.5) |
| Complications | 2.9 (3.6) | 3.5 (3.3) | 0.028 | 0.5 (3.0) | (−0.1 to 1.1) |
| Total | 36.9 (20.8) | 52.6 (29.4) | 0.000 | 15.7 (19.7) | (12.0 to 19.5) |
| Hoehn and Yahr stage (n (%)) | |||||
| 1.0 and 1.5 (unilateral), | 28 (25.2) | 9 (8.1) | |||
| 2.0 and 2.5 (moderate) | 51 (45.9) | 38 (34.2) | |||
| 3.0 (moderate to advanced) | 20 (18.0) | 29 (26.6) | |||
| 4.0 (advanced) | 11 (9.9) | 19 (17.4) | |||
| 5.0 (advanced) | 1 (0.9) | 14 (12.8) | |||
| Mean score (SD) | 2.3 (0.9) | 3.1 (1.0) | 0.000 | 0.7 (0.8) | (0.6 to 0.9) |
| Levodopa dose (mg/day) (mean (SD)) | 512.1 (247.9) | 649.3 (367.5) | 0.000 | 137.1 (279.0) | (83.7 to 190.6) |
| BDI score (mean (SD)) | 11.6 (6.9) | 12.2 (7.2) | 0.369 | 0.6 (8.0) | (−1.0 to 2.2) |
| MMSE score (mean (SD)) | 27.5 (3.4) | 26.2 (5.3) | 0.014 | −1.3 (4.6) | (−2.2 to −0.4) |
| Self reported insomnia (n (%)) | 69 (62.2) | 57 (51.4) | 0.000 | ||
| Wearing off fluctuations (n (%)) | 27 (24.3) | 42 (37.8) | 0.000 | ||
| Presence of dyskinesia (n (%)) | 31 (27.9) | 41 (36.9) | 0.000 | ||